Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial

María E. Miquilena-Colina, Tamara Lozano-Rodríguez, Leonor García-Pozo, Alicia Sáez, Paola Rizza, Imerio Capone, Maria Rapicetta, Paola Chionne, Maria Capobianchi, Marina Selleri, Concetta Castilletti, Filippo Belardelli, Oreste L. Iacono, Carmelo García-Monzón

Research output: Contribution to journalArticle

Abstract

The use of adjuvants capable of improving the deficient immune response to hepatitis B virus (HBV) vaccine in haemodialysis patients is highly needed. Among potential adjuvants, type I interferons deserve a special attention in view of their known effects promoting cellular and humoral immune responses. The aim of the present trial was to evaluate the effects of recombinant interferon-α2b (IFN) administered as an adjuvant of HBV vaccine in unvaccinated haemodialysis patients. A significant and early enhancing effect on the antibody response was observed in patients receiving IFN. In addition, a predominance of IgG1 anti-HBs along with a transient normalization of circulating Th1 lymphocytes was only found in patients receiving IFN who achieved an early seroprotection. However, 6 months after the last vaccine dose, no significant differences were observed in the seroprotection rate achieved in patients vaccinated with IFN compared to that in patients receiving HBV vaccine alone. Mild to moderate fever, asthenia, and arthromyalgia were the most common reactions that occurred in vaccinees given IFN. In conclusion, addition of IFN to HBV vaccine, under the conditions used in this trial, is safe and achieves an earlier and higher seroprotection rate improving Th1-dependent immune response in haemodialysis patients.

Original languageEnglish
Pages (from-to)5654-5660
Number of pages7
JournalVaccine
Volume27
Issue number41
DOIs
Publication statusPublished - Sep 18 2009

Fingerprint

hemodialysis
randomized clinical trials
hepatitis B
interferons
Hepatitis B
Interferons
Renal Dialysis
Vaccination
Randomized Controlled Trials
vaccination
immune response
Hepatitis B Vaccines
Hepatitis B virus
vaccines
adjuvants
Asthenia
Interferon Type I
Humoral Immunity
humoral immunity
Cellular Immunity

Keywords

  • Adjuvant
  • Hepatitis B vaccine
  • Interferon-α

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Miquilena-Colina, M. E., Lozano-Rodríguez, T., García-Pozo, L., Sáez, A., Rizza, P., Capone, I., ... García-Monzón, C. (2009). Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine, 27(41), 5654-5660. https://doi.org/10.1016/j.vaccine.2009.07.014

Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients : Results of a randomised clinical trial. / Miquilena-Colina, María E.; Lozano-Rodríguez, Tamara; García-Pozo, Leonor; Sáez, Alicia; Rizza, Paola; Capone, Imerio; Rapicetta, Maria; Chionne, Paola; Capobianchi, Maria; Selleri, Marina; Castilletti, Concetta; Belardelli, Filippo; Iacono, Oreste L.; García-Monzón, Carmelo.

In: Vaccine, Vol. 27, No. 41, 18.09.2009, p. 5654-5660.

Research output: Contribution to journalArticle

Miquilena-Colina, ME, Lozano-Rodríguez, T, García-Pozo, L, Sáez, A, Rizza, P, Capone, I, Rapicetta, M, Chionne, P, Capobianchi, M, Selleri, M, Castilletti, C, Belardelli, F, Iacono, OL & García-Monzón, C 2009, 'Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial', Vaccine, vol. 27, no. 41, pp. 5654-5660. https://doi.org/10.1016/j.vaccine.2009.07.014
Miquilena-Colina, María E. ; Lozano-Rodríguez, Tamara ; García-Pozo, Leonor ; Sáez, Alicia ; Rizza, Paola ; Capone, Imerio ; Rapicetta, Maria ; Chionne, Paola ; Capobianchi, Maria ; Selleri, Marina ; Castilletti, Concetta ; Belardelli, Filippo ; Iacono, Oreste L. ; García-Monzón, Carmelo. / Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients : Results of a randomised clinical trial. In: Vaccine. 2009 ; Vol. 27, No. 41. pp. 5654-5660.
@article{41228ddfdf5e49e28339f917c52df1b4,
title = "Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial",
abstract = "The use of adjuvants capable of improving the deficient immune response to hepatitis B virus (HBV) vaccine in haemodialysis patients is highly needed. Among potential adjuvants, type I interferons deserve a special attention in view of their known effects promoting cellular and humoral immune responses. The aim of the present trial was to evaluate the effects of recombinant interferon-α2b (IFN) administered as an adjuvant of HBV vaccine in unvaccinated haemodialysis patients. A significant and early enhancing effect on the antibody response was observed in patients receiving IFN. In addition, a predominance of IgG1 anti-HBs along with a transient normalization of circulating Th1 lymphocytes was only found in patients receiving IFN who achieved an early seroprotection. However, 6 months after the last vaccine dose, no significant differences were observed in the seroprotection rate achieved in patients vaccinated with IFN compared to that in patients receiving HBV vaccine alone. Mild to moderate fever, asthenia, and arthromyalgia were the most common reactions that occurred in vaccinees given IFN. In conclusion, addition of IFN to HBV vaccine, under the conditions used in this trial, is safe and achieves an earlier and higher seroprotection rate improving Th1-dependent immune response in haemodialysis patients.",
keywords = "Adjuvant, Hepatitis B vaccine, Interferon-α",
author = "Miquilena-Colina, {Mar{\'i}a E.} and Tamara Lozano-Rodr{\'i}guez and Leonor Garc{\'i}a-Pozo and Alicia S{\'a}ez and Paola Rizza and Imerio Capone and Maria Rapicetta and Paola Chionne and Maria Capobianchi and Marina Selleri and Concetta Castilletti and Filippo Belardelli and Iacono, {Oreste L.} and Carmelo Garc{\'i}a-Monz{\'o}n",
year = "2009",
month = "9",
day = "18",
doi = "10.1016/j.vaccine.2009.07.014",
language = "English",
volume = "27",
pages = "5654--5660",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "41",

}

TY - JOUR

T1 - Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients

T2 - Results of a randomised clinical trial

AU - Miquilena-Colina, María E.

AU - Lozano-Rodríguez, Tamara

AU - García-Pozo, Leonor

AU - Sáez, Alicia

AU - Rizza, Paola

AU - Capone, Imerio

AU - Rapicetta, Maria

AU - Chionne, Paola

AU - Capobianchi, Maria

AU - Selleri, Marina

AU - Castilletti, Concetta

AU - Belardelli, Filippo

AU - Iacono, Oreste L.

AU - García-Monzón, Carmelo

PY - 2009/9/18

Y1 - 2009/9/18

N2 - The use of adjuvants capable of improving the deficient immune response to hepatitis B virus (HBV) vaccine in haemodialysis patients is highly needed. Among potential adjuvants, type I interferons deserve a special attention in view of their known effects promoting cellular and humoral immune responses. The aim of the present trial was to evaluate the effects of recombinant interferon-α2b (IFN) administered as an adjuvant of HBV vaccine in unvaccinated haemodialysis patients. A significant and early enhancing effect on the antibody response was observed in patients receiving IFN. In addition, a predominance of IgG1 anti-HBs along with a transient normalization of circulating Th1 lymphocytes was only found in patients receiving IFN who achieved an early seroprotection. However, 6 months after the last vaccine dose, no significant differences were observed in the seroprotection rate achieved in patients vaccinated with IFN compared to that in patients receiving HBV vaccine alone. Mild to moderate fever, asthenia, and arthromyalgia were the most common reactions that occurred in vaccinees given IFN. In conclusion, addition of IFN to HBV vaccine, under the conditions used in this trial, is safe and achieves an earlier and higher seroprotection rate improving Th1-dependent immune response in haemodialysis patients.

AB - The use of adjuvants capable of improving the deficient immune response to hepatitis B virus (HBV) vaccine in haemodialysis patients is highly needed. Among potential adjuvants, type I interferons deserve a special attention in view of their known effects promoting cellular and humoral immune responses. The aim of the present trial was to evaluate the effects of recombinant interferon-α2b (IFN) administered as an adjuvant of HBV vaccine in unvaccinated haemodialysis patients. A significant and early enhancing effect on the antibody response was observed in patients receiving IFN. In addition, a predominance of IgG1 anti-HBs along with a transient normalization of circulating Th1 lymphocytes was only found in patients receiving IFN who achieved an early seroprotection. However, 6 months after the last vaccine dose, no significant differences were observed in the seroprotection rate achieved in patients vaccinated with IFN compared to that in patients receiving HBV vaccine alone. Mild to moderate fever, asthenia, and arthromyalgia were the most common reactions that occurred in vaccinees given IFN. In conclusion, addition of IFN to HBV vaccine, under the conditions used in this trial, is safe and achieves an earlier and higher seroprotection rate improving Th1-dependent immune response in haemodialysis patients.

KW - Adjuvant

KW - Hepatitis B vaccine

KW - Interferon-α

UR - http://www.scopus.com/inward/record.url?scp=68949170684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949170684&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.07.014

DO - 10.1016/j.vaccine.2009.07.014

M3 - Article

C2 - 19635606

AN - SCOPUS:68949170684

VL - 27

SP - 5654

EP - 5660

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 41

ER -